Entelos is a life sciences company improving human health through predictive biosimulation. Using in silico disease models and a virtual patient approach, Entelos identifies and validates targets, develops biomarkers, improves the success rates of clinical trials, and helps bring therapeutics to market faster.
However, like many in this current economic climate, Entelos company is feeling the bite and today announced that it will seek stockholder approval to cancel the trading of shares of it’s common stock in a bid to secure it’s current debt and develop it’s ‘core business’.
